The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat

Metabolic Brain Disease

Volumn 30, Issue 1, 2015, Pages 205-213

  Zare, Kobra ^a   Eidi, Akram ^a   Roghani, Mehrdad ^b   Rohani, Ali Haeri ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

6 hydroxydopamine; Neuroprotection; Oxidative stress; Parkinson s disease; Sinapic acid

Indexed keywords

ANTIOXIDANT; APOMORPHINE; COUMARIC ACID; IRON; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NITRITE; OXIDOPAMINE; SINAPIC ACID; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TYROSINE 3 MONOOXYGENASE;

ANIMAL; CELL COUNT; CHEMICALLY INDUCED; CHEMISTRY; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; LIPID PEROXIDATION; MALE; MESENCEPHALON; PARKINSONIAN DISORDERS; PATHOLOGY; PHYTOTHERAPY; RANDOMIZATION; RAT; STEREOTYPY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; APOMORPHINE; CELL COUNT; COUMARIC ACIDS; DOPAMINERGIC NEURONS; IRON; LIPID PEROXIDATION; MALE; MESENCEPHALON; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NITRITES; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHYTOTHERAPY; RANDOM ALLOCATION; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TYROSINE 3-MONOOXYGENASE;

EID: 84925513980     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9604-6     Document Type: Article

References (36)

1. Andringa G, van Oosten RV, Unger W, Hafmans TG, Veening J, Stoof JC, Cools AR (2000) Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. Eur J Neurosci 12:3033–3043
2. Baluchnejadmojarad T, Roghani M (2011) Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress. Behav Brain Res 224:305–310
3. Baluchnejadmojarad T, Roghani M, Mafakheri M (2010) Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci Lett 480:206–210
4. Bargiotas P, Konitsiotis S (2013) Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsychiatr Dis Treat 9:1605–1617
5. Bisaglia M, Filograna R, Beltramini M, Bubacco L (2014) Are dopamine derivatives implicated in the pathogenesis of Parkinson’s disease? Ageing Res Rev 13C:107–114
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
7. Chakraborty S, Bornhorst J, Nguyen TT, Aschner M (2013) Oxidative stress mechanisms underlying Parkinson’s disease-associated neurodegeneration in C. elegans. Int J Mol Sci 14:23103–23128
8. Chen S, Le W (2006) Neuroprotective therapy in Parkinson disease. Am J Ther 13:445–457
9. Datla KP, Zbarsky V, Rai D, Parkar S, Osakabe N, Aruoma OI, Dexter DT (2007) Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson’s disease. J Am Coll Nutr 26:341–349
10. De Araujo DP, Lobato Rde F, Cavalcanti JR, Sampaio LR, Araujo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC, Vasconcelos SM (2011) The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson’s disease: a review. Int J Neurosci 121:51–57
11. Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14
12. Foley P, Riederer P (2000) Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease. J Neurol 247(Suppl 2):II82–94
13. Halliday GM, McCann H (2010) The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci 1184:188–195
14. Hattori N (2004) Etiology and pathogenesis of Parkinson’s disease: from mitochondrial dysfunctions to familial Parkinson’s disease. Rinsho Shinkeigaku 44:241–262
15. Jalali-Nadoushan M, Roghani M (2013) Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism. Brain Res 1505:68–74
16. Le W (2014) Role of iron in UPS impairment model of Parkinson’s disease. Parkinsonism Relat Disord 20(Suppl 1):S158–161
17. Lee HE, Kim DH, Park SJ, Kim JM, Lee YW, Jung JM, Lee CH, Hong JG, Liu X, Cai M, Park KJ, Jang DS, Ryu JH (2012) Neuroprotective effect of sinapic acid in a mouse model of amyloid beta (1–42) protein-induced Alzheimer’s disease. Pharmacol Biochem Behav 103:260–266
18. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3:932–942
19. Pari L, Mohamed Jalaludeen A (2011) Protective role of sinapic acid against arsenic: induced toxicity in rats. Chem Biol Interact 194:40–47
20. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, San Diego
21. Qiao HY, Dahiya JP, Classen HL (2008) Nutritional and physiological effects of dietary sinapic acid (4-hydroxy-3,5-dimethoxy-cinnamic acid) in broiler chickens and its metabolism in the digestive tract. Poult Sci 87:719–726
22. Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T (2010) Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull 82:279–283
23. Roy SJ, Mainzen Prince PS (2013) Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats. Eur J Pharmacol 699:213–218
24. Roy SJ, Stanely Mainzen Prince P (2012) Protective effects of sinapic acid on lysosomal dysfunction in isoproterenol induced myocardial infarcted rats. Food Chem Toxicol 50:3984–3989
25. Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson’s disease. Mov Disord 26:1049–1055
26. Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res 318:215–224
27. Shapiro RM, Glick SD, Camarota NA (1987) A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res 426:323–331
28. Shin DS, Kim KW, Chung HY, Yoon S, Moon JO (2013) Effect of sinapic acid against carbon tetrachloride-induced acute hepatic injury in rats. Arch Pharm Res 36:626–633
29. Smith Y, Wichmann T, Factor SA, DeLong MR (2012) Parkinson’s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 37:213–246
30. Sriram K, O’Callaghan JP (2007) Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2:140–153
31. Tapias V, Cannon JR, Greenamyre JT (2013) Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson’s disease. Neurobiol Aging 35:1162–1176
32. Von Bohlen und Halbach O, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson’s disease. Prog Neurobiol 73:151–177
33. Wang J, Xu H, Jiang H, Du X, Sun P, Xie J (2012) Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson’s disease. J Mol Neurosci 47:113–119
34. Weinreb O, Mandel S, Youdim MB, Amit T (2013) Targeting dysregulation of brain iron homeostasis in Parkinson’s disease by iron chelators. Free Radic Biol Med 62:52–64
35. Yun KJ, Koh DJ, Kim SH, Park SJ, Ryu JH, Kim DG, Lee JY, Lee KT (2008) Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation. J Agric Food Chem 56:10265–10272
36. Zhou ZD, Refai FS, Xie SP, Ng SH, Chan CH, Ho PG, Zhang XD, Lim TM, Tan EK (2013) Mutant PINK1 upregulates tyrosine hydroxylase and dopamine levels, leading to vulnerability of dopaminergic neurons. Free Radic Biol Med 68C:220–233